menu
    • menu
    [{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement C5","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement C5","graph1":"Immunology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"oral","sponsorNew":"CSL Vifor \/ Amgen Inc","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Amgen Inc"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement C5","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Satralizumab","moa":"IL-6 receptor","graph1":"Neurology","graph2":"Approved","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Azathioprine

    Menu

    Azathioprine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    F. Hoffmann-La Roche

    Switzerland arrow
    BePharma
    Not Confirmed

    F. Hoffmann-La Roche

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Satralizumab,Azathioprine,Mycophenolate Mofetil

    Therapeutic Area : Neurology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Roche’s Enspryng Leads Latest CHMP Recommendations

    Details : Leading those recommendations is Roche’s Enspryng (satralizumab), which received a positive opinion for the treatment of the rare autoimmune disease neuromyelitis optica spectrum disorders (NMOSD).

    Product Name : Enspryng

    Product Type : Large molecule

    Upfront Cash : Not Applicable

    April 23, 2021

    Lead Product(s) : Satralizumab,Azathioprine,Mycophenolate Mofetil

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Amgen Inc

    U.S.A arrow
    BePharma
    Not Confirmed

    Amgen Inc

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Avacopan,Rituximab,Azathioprine

    Therapeutic Area : Immunology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    ChemoCentryx Announces Plenary Session at ACR Convergence 2020 to Highlight Data from ADVOCATE Phase III Trial...

    Details : The study showed that avacopan was as effective as prednisone therapy in bringing patients into remission by 26 weeks, and superior to prednisone for sustained remission after 52 weeks.

    Product Name : CCX168

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    November 06, 2020

    Lead Product(s) : Avacopan,Rituximab,Azathioprine

    Therapeutic Area : Immunology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    CSL Vifor

    Switzerland arrow
    BePharma
    Not Confirmed

    CSL Vifor

    Switzerland arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Avacopan,Rituximab,Azathioprine

    Therapeutic Area : Immunology

    Study Phase : Phase III

    Sponsor : Amgen Inc

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    VFMCRP and ChemoCentryx Announce European Medicines Agency has Accepted to Review the Marketing Authorization ...

    Details : If approved, avacopan would be the first orally administered selective complement 5a receptor inhibitor, for the treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.

    Product Name : CCX168

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    November 03, 2020

    Lead Product(s) : Avacopan,Rituximab,Azathioprine

    Therapeutic Area : Immunology

    Highest Development Status : Phase III

    Sponsor : Amgen Inc

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Amgen Inc

    U.S.A arrow
    BePharma
    Not Confirmed

    Amgen Inc

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Avacopan,Rituximab,Azathioprine

    Therapeutic Area : Immunology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Ass...

    Details : The NDA included data from the global, Phase III ADVOCATE trial, which demonstrated statistical superiority in sustaining remission at 52 weeks in the avacopan group compared to the prednisone group.

    Product Name : CCX168

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    September 17, 2020

    Lead Product(s) : Avacopan,Rituximab,Azathioprine

    Therapeutic Area : Immunology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth